Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence

Already used for the treatment of some allergic and inflammatory diseases, such as asthma or atopic dermatitis, dupilumab has also been approved as add-on therapy for patients with CRSwNP, and it could represent the keystone to reducing the remission time as well as to improve healing and quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimmi, Selena, Lombardo, Nicola, Maisano, Domenico, Piazzetta, Giovanna, Pelaia, Corrado, Pelaia, Girolamo, Greco, Marta, Foti, Daniela, Dattilo, Vincenzo, Iaccino, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777725/
https://www.ncbi.nlm.nih.gov/pubmed/36553635
http://dx.doi.org/10.3390/genes13122366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777725/
https://www.ncbi.nlm.nih.gov/pubmed/36553635
http://dx.doi.org/10.3390/genes13122366

Ejemplares similares